Lessons from the FDA for AI
AI Now Institute draws on FDA pharmaceutical regulation as a model for ex ante AI regulatory design.
Key points
- The report examines premarket scrutiny, regulatory functions, and industry capture risks - all live questions for Australian AI governance.
- Published mid-2024; the political climate the authors describe as hostile to premarket AI enforcement remains broadly unchanged.